一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

Raloxifene

Raloxifene ??? ???
?? ??:
84449-90-1
???:
Raloxifene
???(??):
RALOXIFEN;Evista;(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)Methanone;RALOXAFINE;RALOXIFENE;RALOXIFENE-D7;Raloxifene CRS;LY156758 free base;Raloxifene USP/EP/BP;Raloxifene hydrochlo
CBNumber:
CB1290431
???:
C28H27NO4S
??? ??:
473.58
MOL ??:
84449-90-1.mol

Raloxifene ??

???
250-253°C
?? ?
728.2±60.0 °C(Predicted)
??
1.289±0.06 g/cm3(Predicted)
?? ??
Desiccate at +4°C
???
DMSO: 28mg/mL, ???
??? ??
??
??? ??
??? ??
?? ?? (pKa)
8.83±0.15(Predicted)
??
???
???
560μg/L at 25℃
InChI
InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2
InChIKey
GZUITABIAKMVPG-UHFFFAOYSA-N
SMILES
C(C1=C(C2=CC=C(O)C=C2)SC2=CC(O)=CC=C21)(C1=CC=C(OCCN2CCCCC2)C=C1)=O
LogP
6.09
CAS ??????
84449-90-1(CAS DataBase Reference)
??
  • ?? ? ?? ??
  • ?? ? ???? ?? (GHS)
WGK ?? 3
HS ?? 29349990
?? ?? ??? 84449-90-1(Hazardous Substances Data)
????(GHS): Health Hazard (GHS08)Environment (GHS09)Skull and Crossbones (GHS06)
?? ?: Danger
??·?? ??:
?? ??·?? ?? ?? ?? ?? ?? ? ?? ?? P- ??
H311 ??? ???? ??? ?? ?? ?? - ?? ?? 3 ?? P280, P302+P352, P312, P322, P361,P363, P405, P501
H360 ?? ?? ????? ??? ??? ? ?? ???? ?? ?? 1A, 1B ??
H411 ??? ??? ?? ????? ??? ?? ????? ?? - ?? ?? 2
??????:
P280 ????/???/???/?????? ?????.
P302+P352 ??? ??? ??? ?? ????.
P312 ???? ??? ????(??)? ??? ????.
P322 ?? ??(??? … ??)
P361 ?? ??? ??? ?? ?? ?
P363 ?? ??? ??? ??? ?????.
P405 ???? ?????.
P501 ...? ??? / ??? ?? ???.

Raloxifene MSDS


Raloxifene

Raloxifene C??? ??, ??, ??

??? ??

Light-Yellow Solid

??

Raloxifene is a nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.

Indications

Raloxifene (Evista) is a new SERM approved for use in the treatment and prevention of osteoporosis because it has estrogenic activity in bone. Raloxifene is an estrogen antagonist in both breast and endometrial tissues. The estrogenlike properties of raloxifene result in the maintenance of a favorable serum lipid profile (decreased low-density lipoprotein levels with no change in either high-density lipoproteins or triglycerides). Raloxifene is 95% bound to plasma proteins. Absorption of raloxifene is impaired by cholestyramine.

??

ChEBI: A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.

?? ??

Raloxifene, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone (Evista), is a benzothiophene derivativethat differs slightly from the triphenylethyleneSERMs. A key structural difference is the carbonyl “hinge”that connects the modified phenolic side chain to the benzothiophenering system. This hinge is the key structural elementthat leads to the differing actions at the ERs.Raloxifene, unlike tamoxifen and toremifene, has antagonistproperties on the endometrium and breast tissue and agonistproperties on bone and the cardiovascular system. The lackof agonist action on endometrial tissue has been suggestedas a reason for the lack of endometrial cancer associatedwith raloxifene use. Raloxifene is approved for the preventionand treatment of osteoporosis in postmenopausalwomen. It has also been investigated for preventing breastcancer in comparison with tamoxifen. Recent studies indicatesthat it has similar effectiveness to tamoxifen, but has apreferable side effect profile.

???? ??

Selective estrogen receptor modulator (SERM) that binds to ER α and ER β , and tissue-dependently activates or blocks estrogen-induced transcription. Acts as an antiestrogen in breast and uterine tissue, but displays estrogen agonist activity in bone. In D12 rat hypothalamic cells, inhibits progesterone receptor induction by estrogen with an IC 50 of 1 nM.

Clinical Use

Raloxifene, the first SERM approved for the prevention of osteoporosis in postmenopausal women, acts as an estrogen agonist on receptors in osteoblasts and osteoclasts but as an antagonist at breast and uterine estrogen receptors.

Raloxifene ?? ?? ? ???

???

?? ??


Raloxifene ?? ??

???( 169)?? ??
??? ?? ??? ?? ?? ? ??
Dingwang Technology (Wuhan) Co., Ltd.
+undefined-27-2786652399 +undefined13627115097
market02@senwayer.com China 887 58
Anhui Ruihan Technology Co., Ltd
+undefined17756083858
daisy@anhuiruihan.com China 973 58
Shaanxi Xianhe Biotech Co., Ltd
+86-17709210191; +86-17709210191
Jerry@xhobio.com China 906 58
Rongchuang International
+86-13175533356 +86-13175533356
kevin@rongchuangintl.com China 257 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21585 55
career henan chemical co
+86-0371-86658258
sales@coreychem.com China 29812 58
Xiamen AmoyChem Co., Ltd
+86-86-5926051114
sales@amoychem.com China 6366 58
CONIER CHEM AND PHARMA LIMITED

sales@conier.com China 49979 58
Chengdu Aslee Biopharmaceuticals, Inc.
28-85305008
CHINA 964 58
Hubei Ipure Biology Co., Ltd
+8618062405514
ada@ipurechemical.com China 10236 58

Raloxifene ?? ??:

Copyright 2019 ? ChemicalBook. All rights reserved
神池县| 彭阳县| 平顺县| 盐亭县| 紫阳县| 定边县| 甘洛县| 南郑县| 巧家县| 合山市| 来宾市| 赣州市| 泰来县| 金平| 嵊州市| 双鸭山市| 柳林县| 乳源| 南岸区| 虎林市| 临城县| 浦北县| 厦门市| 玉龙| 随州市| 红安县| 大足县| 金平| 松潘县| 商都县| 武隆县| 高清| 黎川县| 遂溪县| 闻喜县| 广东省| 新沂市| 灌阳县| 和田市| 喀喇| 安泽县|